Pure Global AI
NCT06398743Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Exact Sciences CorporationClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
MRD
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Exact Sciences Corporation
Location
Afula,Jerusalem,Rozzano,Milano,Napoli,Madrid,Madrid,Edinburgh,Ipswich,Torquay, Israel,Italy,Spain,United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Jun 20, 2023
End date
Jun 15, 2029
Enrollment
400 participants
Primary outcome

To validate the association of post-definitive therapy and pre-recurrence follow-up ctDNA positivity with Recurrence Free Interval, defined as elapsed time from surgical resection to the first clinical recurrence or CRC-related death.

Summary

The CORRECT - MRD I study will prospectively enroll patients who have undergone complete
 surgical resection for stage II or III colorectal cancer. Patients will be followed for up to
 5 years for recurrence.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06398743
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06398743 through Pure Global AI's free database. This phase not specified trial is sponsored by Exact Sciences Corporation and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.